Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
Purpose Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to describe the real-world long-term effectiveness of ixekizumab in patients with plaque psoriasi...
Sparad:
Huvudskapare: | , , , , , , , , , , , , |
---|---|
Materialtyp: | Bok |
Publicerad: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Ämnen: | |
Länkar: | Connect to this object online. |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
Signum: |
A1234.567 |
---|---|
Exemplar 1 | Tillgänglig |